AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29747625 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet cluster (oral health education through leaflets)
Number of subjects: 220
Study 29747625 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet cluster
Number of subjects: 220
Study 29747625 — intervention group
Group type: COMPARATOR
Intervention: E-learning cluster (oral health education through E-learning program)
Number of subjects: 220
Study 29747625 — intervention group
Group type: EXPERIMENTAL
Intervention: Both clusters
Number of subjects: 220
Study 27025586 — intervention group
Group type: COMPARATOR
Intervention: Endocrine Treatment (ET) alone
Number of subjects: 875
Study 27025586 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine Treatment (ET) + Radiotherapy (RAD)
Number of subjects: 875
Study 25036199 — intervention group
Group type: EXPERIMENTAL
Intervention: Dural suturing with TachoSil
Number of subjects: 229
Study 25036199 — intervention group
Group type: COMPARATOR
Intervention: Dural suturing alone (Control)
Number of subjects: 229
Study 22418829 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT‐077825 (1-1,000 mg)
Number of subjects: 70
Study 22418829 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 20 mg
Number of subjects: 70
Study 22418829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 20329580 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 22
Study 20329580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 18715218 — intervention group
Group type: COMPARATOR
Intervention: 1,000 mg of CrPic for 8 weeks
Number of subjects: 42
Study 18715218 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal administration of CrPic (0, 1, 10, or 50 microg/kg)
Number of subjects: 42
Study 18715218 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracerebroventricular administration of CrPic (0, 0.4, 4, or 40 ng)
Number of subjects: 42
Study 16439811 — intervention group
Group type: EXPERIMENTAL
Intervention: Petrolatum-based ointments
Number of subjects: 16
Study 16439811 — intervention group
Group type: COMPARATOR
Intervention: Non-alcohol barrier film
Number of subjects: 16
Study 12859474 — intervention group
Group type: EXPERIMENTAL
Intervention: Curved bougie
Number of subjects: 30
Study 12859474 — intervention group
Group type: EXPERIMENTAL
Intervention: Coudé-tipped bougie
Number of subjects: 30
Study 12859474 — intervention group
Group type: COMPARATOR
Intervention: Straight bougie
Number of subjects: 30
Study 12859474 — intervention group
Group type: COMPARATOR
Intervention: Straight straight-tipped bougie
Number of subjects: 30
Study 10376614 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL 12.5 mg (NYHA III‐IV) or 25.0 mg once daily (NYHA II), target dose 200 mg once daily, up-titrated over 8 weeks
Number of subjects: 3991
Study 10376614 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL
Number of subjects: 3991
Study 10376614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3991
Study 8708804 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytobrush
Number of subjects: 252
Study 8708804 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayre spatula plus Cytobrush
Number of subjects: 252
Study 8708804 — intervention group
Group type: COMPARATOR
Intervention: Ayre spatula plus cotton swab
Number of subjects: 252
Study 1809418 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency nonpainful TENS
Number of subjects: 0
Study 1809418 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 0
Study 6401193 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-deamino-8-D-arginine vasopressin
Number of subjects: 12
Study 6401193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30882963 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide-field enhanced-depth imaging optical coherence tomography
Number of subjects: 27
Study 29211888 — intervention group
Group type: EXPERIMENTAL
Intervention: OCP + BC (50 mg/d)
Number of subjects: 70
Study 29211888 — intervention group
Group type: COMPARATOR
Intervention: OCP + P
Number of subjects: 70
Study 26725050 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar tendon autograft (n = 31)
Number of subjects: 62
Study 26725050 — intervention group
Group type: COMPARATOR
Intervention: Semitendinosus tendon autograft (n = 31)
Number of subjects: 62
Study 24469526 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic psychotherapy plus adjunctive pharmacotherapy
Number of subjects: 33
Study 24469526 — intervention group
Group type: COMPARATOR
Intervention: Multimodal psychodynamic psychotherapy only
Number of subjects: 33
Study 22698700 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 μg of misoprostol
Number of subjects: 400
Study 22698700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 19857859 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpretation modification condition (benign interpretive bias)
Number of subjects: 0
Study 19857859 — intervention group
Group type: COMPARATOR
Intervention: Control condition (accessing threat and benign meanings with equal frequency)
Number of subjects: 0
Study 16943401 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg daily
Number of subjects: 1561
Study 16943401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1561
Study 14502372 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin estolate, 20 mg kg‐1 day‐1, divided into four oral doses for 4 weeks
Number of subjects: 14
Study 14502372 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 14
Study 10732392 — intervention group
Group type: EXPERIMENTAL
Intervention: Saw palmetto extract (SPE) 160 mg standardized extract twice daily
Number of subjects: 1
Study 10732392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 10732392 — intervention group
Group type: EXPERIMENTAL
Intervention: Saw palmetto extract (SPE)
Number of subjects: 1
Study 8909345 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy
Number of subjects: 210
Study 1327632 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquorice (7 days of oral administration)
Number of subjects: 0
Study 1327632 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital 11 beta‐hydroxysteroid dehydrogenase deficiency
Number of subjects: 0
Study 1327632 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol (intra-arterial infusion)
Number of subjects: 0
Study 1327632 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenoxolone
Number of subjects: 0
Study 3901992 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephamandole (1 g single dose given 1 hour before surgery)
Number of subjects: 200
Study 3901992 — intervention group
Group type: COMPARATOR
Intervention: Placebo (given 1 hour before surgery)
Number of subjects: 200
Study 3901992 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephamandole (1 g single dose)
Number of subjects: 200
Study 31987548 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching
Number of subjects: 13
Study 31987548 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 13
Study 30481690 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal stimulation
Number of subjects: 77
Study 30481690 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal stimulation
Number of subjects: 77
Study 30481690 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 77
Study 30481690 — intervention group
Group type: COMPARATOR
Intervention: N-back task (control task)
Number of subjects: 77
Study 29318159 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 310
Study 29318159 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 310
Study 25760565 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 97
Study 25760565 — intervention group
Group type: COMPARATOR
Intervention: d4T or ZDV (Control)
Number of subjects: 97
Study 23350632 — intervention group
Group type: EXPERIMENTAL
Intervention: Lodenafil
Number of subjects: 50
Study 23350632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 20493567 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril or Losartan (not specified dosage or duration)
Number of subjects: 233
Study 19186906 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral mirroring by a confederate
Number of subjects: 2
Study 19186906 — intervention group
Group type: COMPARATOR
Intervention: No behavioral mirroring by a confederate
Number of subjects: 2
Study 16719233 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 to 8 mg daily)
Number of subjects: 20
Study 16719233 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide (3.5 to 10.5 mg daily)
Number of subjects: 20
Study 15458525 — intervention group
Group type: EXPERIMENTAL
Intervention: 595‐nm pulsed dye laser + 1450‐nm diode laser (Group A)
Number of subjects: 30
Study 15458525 — intervention group
Group type: COMPARATOR
Intervention: 595‐nm pulsed dye laser (Group B)
Number of subjects: 30
Study 15458525 — intervention group
Group type: COMPARATOR
Intervention: 1450‐nm diode laser (Group C)
Number of subjects: 30
Study 11413528 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy (various protocols including intraarterial and intravenous epirubicin, oral tegafur, carmofur)
Number of subjects: 108
Study 11413528 — intervention group
Group type: COMPARATOR
Intervention: Resection alone
Number of subjects: 108
Study 9688399 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-culture with Vero cells
Number of subjects: 11
Study 8185465 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke rehabilitation services
Number of subjects: 0
Study 8185465 — intervention group
Group type: COMPARATOR
Intervention: Varying levels of rehabilitation services
Number of subjects: 0
Study 2817770 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet rich in starch (300 grams)
Number of subjects: 6
Study 2817770 — intervention group
Group type: COMPARATOR
Intervention: Diet low in starch (100 grams)
Number of subjects: 6
Study 802975 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthetic (sensory deprivation of the oral cavity via nerve-block injections)
Number of subjects: 6
Study 802975 — intervention group
Group type: COMPARATOR
Intervention: Placebo (insertions of a hypodermic needle without anesthetic)
Number of subjects: 6
Study 802975 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 6
Study 31311067 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic lupus erythematosus
Number of subjects: 7240
Study 31311067 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic lupus erythematosus (adjusted)
Number of subjects: 7240
Study 31311067 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥45 years (adjusted)
Number of subjects: 7240
Study 31311067 — intervention group
Group type: COMPARATOR
Intervention: Non-systemic lupus erythematosus (control)
Number of subjects: 7240
Study 29095376 — intervention group
Group type: EXPERIMENTAL
Intervention: Triacylglycerol 50:2
Number of subjects: 30
Study 29095376 — intervention group
Group type: COMPARATOR
Intervention: Phosphoglyceride 34:2
Number of subjects: 30
Study 29095376 — intervention group
Group type: COMPARATOR
Intervention: Plasmenyl phosphocholine 38:1
Number of subjects: 30
Study 29095376 — intervention group
Group type: COMPARATOR
Intervention: Phosphatidic acid 28:1
Number of subjects: 30
Study 29095376 — intervention group
Group type: EXPERIMENTAL
Intervention: Four statistically significant lipids
Number of subjects: 30
Study 25179493 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 189
Study 25179493 — intervention group
Group type: COMPARATOR
Intervention: Adefovir dipivoxil
Number of subjects: 189
Study 23112341 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate circumcision
Number of subjects: 0
Study 23112341 — intervention group
Group type: COMPARATOR
Intervention: Delayed circumcision (control)
Number of subjects: 0
Study 21467538 — intervention group
Group type: EXPERIMENTAL
Intervention: Visionary leaders (those who offer novel solutions)
Number of subjects: 5
Study 21467538 — intervention group
Group type: COMPARATOR
Intervention: Representative leaders
Number of subjects: 5
Study 18342989 — intervention group
Group type: EXPERIMENTAL
Intervention: Temptation group instructed to abstain from a favourite snack for 24h while being exposed to it.
Number of subjects: 68
Study 18342989 — intervention group
Group type: COMPARATOR
Intervention: Control group with no specific instructions.
Number of subjects: 68
Study 16575425 — intervention group
Group type: EXPERIMENTAL
Intervention: slow rTMS over the left OFC
Number of subjects: 12
Study 16575425 — intervention group
Group type: COMPARATOR
Intervention: placebo treatment over the left OFC
Number of subjects: 12
Study 16575425 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS over the left dorsolateral portion of the prefrontal cortex
Number of subjects: 12
Study 12752077 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife performed ET
Number of subjects: 102
Study 12752077 — intervention group
Group type: COMPARATOR
Intervention: Gynecologist performed ET
Number of subjects: 102
Study 11493164 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer disease without stroke (possible and probable)
Number of subjects: 339
Study 11493164 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia with cerebrovascular disease
Number of subjects: 339
Study 11493164 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged 80 years and older with dementia with cerebrovascular disease
Number of subjects: 339
Study 11493164 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients younger than 80 years with dementia with cerebrovascular disease
Number of subjects: 339
Study 9249774 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate anticoagulation
Number of subjects: 10
Study 9249774 — intervention group
Group type: COMPARATOR
Intervention: Heparin anticoagulation
Number of subjects: 10
Study 8126317 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.6 mg/kg)
Number of subjects: 288
Study 8126317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study 8126317 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate first followed by placebo
Number of subjects: 288
Study 8126317 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo first followed by methylphenidate
Number of subjects: 288
Study 2965135 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin 400 mg daily
Number of subjects: 21
Study 2965135 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin 1 g bd
Number of subjects: 21
Study 2965135 — intervention group
Group type: COMPARATOR
Intervention: Both regimens
Number of subjects: 21
Study 29316570 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial removable dental prosthesis (PRDP) group
Number of subjects: 152
Study 29316570 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened dental arch (SDA) group
Number of subjects: 152
Study 29316570 — intervention group
Group type: COMPARATOR
Intervention: Age (covariate)
Number of subjects: 152
Study 29316570 — intervention group
Group type: COMPARATOR
Intervention: DMFT value (covariate)
Number of subjects: 152
Study 27898460 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone pain app with 2-way messaging, N=52
Number of subjects: 105
Study 27898460 — intervention group
Group type: COMPARATOR
Intervention: Smartphone pain app without 2-way messaging
Number of subjects: 105
Study 27898460 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups using the smartphone pain app
Number of subjects: 105
Study 24815417 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 0.1 mg·kg(‐1) with acetaminophen 40 mg·kg(‐1) before surgery and 20 mg·kg(‐1) rectally at the end of surgery
Number of subjects: 151
Study 24815417 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 0.5 mg·kg(‐1) with acetaminophen 40 mg·kg(‐1) before surgery and 20 mg·kg(‐1) rectally at the end of surgery
Number of subjects: 151
Study 24815417 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 2.0 mg·kg(‐1) with acetaminophen 40 mg·kg(‐1) before surgery and 20 mg·kg(‐1) rectally at the end of surgery
Number of subjects: 151
Study 24815417 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 0.1 mg·kg(‐1) only
Number of subjects: 151
Study 24815417 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 0.5 mg·kg(‐1) only
Number of subjects: 151
Study 24815417 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 2.0 mg·kg(‐1) only
Number of subjects: 151
Study 24815417 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen 30 mg·kg(‐1)
Number of subjects: 151
Study 24815417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 22791166 — intervention group
Group type: EXPERIMENTAL
Intervention: Elcatonin (ECT) 20 units intramuscularly per week
Number of subjects: 61
Study 22791166 — intervention group
Group type: COMPARATOR
Intervention: Risedronate (17.5 mg weekly)
Number of subjects: 61
Study 20124282 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia
Number of subjects: 60
Study 20124282 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled i.v. opiate analgesia (PCA)
Number of subjects: 60
Study 17586782 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50-100 mg/day
Number of subjects: 747
Study 17586782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 747
Study 16128676 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mixture containing Lactobacillus rhamnosus GG, L. rhamnosus LC705, Bifidobacterium breve Bb99, and Propionibacterium freudenreichii ssp. shermanii JS, taken daily for 6 months.
Number of subjects: 103
Study 16128676 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule taken daily for 6 months.
Number of subjects: 103
Study 16128676 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mixture
Number of subjects: 103
Study 12450692 — intervention group
Group type: EXPERIMENTAL
Intervention: COMVAX plus placebo
Number of subjects: 1215
Study 12450692 — intervention group
Group type: COMPARATOR
Intervention: PedvaxHIB plus RECOMBIVAX HB
Number of subjects: 1215
Study 10086942 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventstream nebuliser (MMD, 3.3 microm; delivery rate, 0.075 ml/min)
Number of subjects: 33
Study 10086942 — intervention group
Group type: COMPARATOR
Intervention: Optimist nebuliser (MMD, 1.8 microm; delivery rate, 0.02 ml/min)
Number of subjects: 33
Study 10086942 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both nebulisers in 20 patients
Number of subjects: 33
Study 7822046 — intervention group
Group type: EXPERIMENTAL
Intervention: Live oral cholera vaccine CVD 103-HgR
Number of subjects: 0
Study 7822046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2239116 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg 0.5% bupivacaine after free drops of CSF (Group I)
Number of subjects: 66
Study 2239116 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg 0.5% bupivacaine after removal of 3 ml CSF (Group II)
Number of subjects: 66
Study 2239116 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg 0.5% bupivacaine after removal of 5 ml CSF (Group III)
Number of subjects: 66
Study 497087 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide administration
Number of subjects: 7
Study 497087 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide administration
Number of subjects: 7
Study 497087 — intervention group
Group type: COMPARATOR
Intervention: Both intravenous and oral cyclophosphamide administration
Number of subjects: 7
Study 31918431 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 34
Study 29952697 — intervention group
Group type: EXPERIMENTAL
Intervention: ReBound diathermy
Number of subjects: 3
Study 29952697 — intervention group
Group type: COMPARATOR
Intervention: Moist hot packs
Number of subjects: 3
Study 29952697 — intervention group
Group type: COMPARATOR
Intervention: MegaPulse II pulsed shortwave diathermy
Number of subjects: 3
Study 25036048 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepavax-Gene thiomersal-containing (TC)
Number of subjects: 0
Study 25036048 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepavax-Gene thiomersal-free (TF)
Number of subjects: 0
Study 23378064 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg
Number of subjects: 0
Study 23378064 — intervention group
Group type: COMPARATOR
Intervention: Fulvestrant 250 mg
Number of subjects: 0
Study 23378064 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of Fulvestrant 500 mg to Fulvestrant 250 mg
Number of subjects: 0
Study 21098066 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (six-month trainer-supervised program)
Number of subjects: 39
Study 21098066 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (education session with monthly phone follow-ups)
Number of subjects: 39
Study 20183536 — intervention group
Group type: EXPERIMENTAL
Intervention: Videobike gaming
Number of subjects: 29
Study 20183536 — intervention group
Group type: COMPARATOR
Intervention: Self-selected music cycling (comparison condition)
Number of subjects: 29
Study 17684085 — intervention group
Group type: EXPERIMENTAL
Intervention: End-range mobilization (ERM)
Number of subjects: 28
Study 17684085 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization with movement (MWM)
Number of subjects: 28
Study 17684085 — intervention group
Group type: COMPARATOR
Intervention: Mid-range mobilization (MRM)
Number of subjects: 28
Study 16724337 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial portal revascularization
Number of subjects: 60
Study 16724337 — intervention group
Group type: COMPARATOR
Intervention: Initial arterial revascularization
Number of subjects: 60
Study 12599046 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-milk ingestion
Number of subjects: 0
Study 12599046 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding per day
Number of subjects: 0
Study 12599046 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced maternal disease (measured by prenatal HIV-1 RNA plasma levels and CD4 cell counts)
Number of subjects: 0